These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 33100195)
1. COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus. Tavakol S; Alavijeh MS; Seifalian AM Curr Pharm Des; 2021; 27(13):1553-1563. PubMed ID: 33100195 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
3. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
4. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802 [TBL] [Abstract][Full Text] [Related]
5. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Flanagan KL; Best E; Crawford NW; Giles M; Koirala A; Macartney K; Russell F; Teh BW; Wen SC Front Immunol; 2020; 11():579250. PubMed ID: 33123165 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896 [TBL] [Abstract][Full Text] [Related]
7. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector]. Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356 [TBL] [Abstract][Full Text] [Related]
13. Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. Biswas A; Mandal RS; Chakraborty S; Maiti G Int Rev Immunol; 2022; 41(4):448-463. PubMed ID: 33978550 [TBL] [Abstract][Full Text] [Related]
14. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. de Queiroz NMGP; Marinho FV; Chagas MA; Leite LCC; Homan EJ; de Magalhães MTQ; Oliveira SC Microbes Infect; 2020; 22(10):515-524. PubMed ID: 32961274 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177 [TBL] [Abstract][Full Text] [Related]
16. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein. Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955 [TBL] [Abstract][Full Text] [Related]
17. Development of vaccines for SARS-CoV-2. Ng WH; Liu X; Mahalingam S F1000Res; 2020; 9():. PubMed ID: 32850116 [TBL] [Abstract][Full Text] [Related]
18. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Wang F; Kream RM; Stefano GB Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816 [TBL] [Abstract][Full Text] [Related]
19. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development. Banerjee A; Santra D; Maiti S J Transl Med; 2020 Jul; 18(1):281. PubMed ID: 32650788 [TBL] [Abstract][Full Text] [Related]
20. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Gao T; Ren Y; Li S; Lu X; Lei H Microb Cell Fact; 2021 May; 20(1):95. PubMed ID: 33952256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]